Austin Erlich

Overlord Labs is building battery intelligence infrastructure for the next generation of compute-intensive, battery-powered devices. Powered by our proprietary Silicon × Algorithm Architecture, we integrate advanced battery intelligence directly into silicon, enabling OEMs to deliver longer runtime, improved safety, higher performance, and greater design flexibility. Initially focused on wearables, smart glasses, and edge AI devices, our platform is designed to scale across a broad range of battery-powered systems.

VALFIX Medical is an early-stage fast-moving start-up company. VALFIX Medical is developing a complete transcatheter repair solution, based on its multi-wire technology, offering a viable alternative to open-heart valve surgery. VALFIX technology is designed to eliminate mitral regurgitation (MR) in over 90% of severe MR patients VALFIX is creating a solution that is the closest to the surgical standard in transcatheter mitral valve repair and replacement The Need/Opportunity: Mitral regurgitation (MR) is one of the most prevalent and disabling heart conditions worldwide. Currently, the standard treatment for severe MR is open heart surgery. Globally there are more than 15 million Mitral Regurgitation patients, 4.5 million are suffering from severe MR. Only 2% of the 4.5 million severe MR patients undergo open heart surgery. The remaining 98% are sent home with drug therapy alone, resulting in nearly 50% of them dying within 2 years. The current available treatments for MR patients with heart failure are limited. Surgical repair and replacement are controversial, and new treatments are insufficient. To learn more about VALFIX Medical visit our website at www.valfixmed.com or contact us directly at info@valfixmed.com

To help all parents build a better future for their kids

Overlord Labs is building battery intelligence infrastructure for the next generation of compute-intensive, battery-powered devices. Powered by our proprietary Silicon × Algorithm Architecture, we integrate advanced battery intelligence directly into silicon, enabling OEMs to deliver longer runtime, improved safety, higher performance, and greater design flexibility. Initially focused on wearables, smart glasses, and edge AI devices, our platform is designed to scale across a broad range of battery-powered systems.

The Band of Angels is Silicon Valleys oldest seed funding organization. We are a formal group of more than 150 former and current high tech executives who are interested in investing their time and money into new, cutting edge, startup companies. Weve seeded over 277 companies in our history with 61 profitable M&A exits and 11 IPOs. Band members have founded companies such as Symantec, Logitech, and National Semiconductor and been senior executives at the likes of Sun Microsystems, Hewlett Packard, and Intuit. The Band meets monthly to formally consider three startups selected from among the more than 50 that are screened each month by the Band Deal Selection Process. Entrepreneurs can expect a thorough examination and, occasionally, an investment from some of Silicon Valleys most accomplished entrepreneurs.

Kyto Technology and Life Science, Inc., formerly Kyto Biopharma, Inc., seeks to develop a specialized vehicle for early stage technology and life science companies. The Company operates as a mentor, advisor, external manager and investor for selected privately held companies in the United States of America, Canada and Israel. The Companys portfolio includes CNote Group, Inc. (CNote), Exodos/Achelios Therapeutics, Inc. (Achelios), Seal Rock Therapeutics, Inc., and Crater, LLC (Crater). CNote provides an alternative savings product that pays up to 35x the interest of a traditional savings account. Crater provides the SurveyBot software program, which enables video chat between a moving companys representative and the customer. Achelios is a specialty pharmaceutical company with primary focus on new therapeutic entity (NTE) development for the treatment of pain and inflammation by delivered medications.

VALFIX Medical is an early-stage fast-moving start-up company. VALFIX Medical is developing a complete transcatheter repair solution, based on its multi-wire technology, offering a viable alternative to open-heart valve surgery. VALFIX technology is designed to eliminate mitral regurgitation (MR) in over 90% of severe MR patients VALFIX is creating a solution that is the closest to the surgical standard in transcatheter mitral valve repair and replacement The Need/Opportunity: Mitral regurgitation (MR) is one of the most prevalent and disabling heart conditions worldwide. Currently, the standard treatment for severe MR is open heart surgery. Globally there are more than 15 million Mitral Regurgitation patients, 4.5 million are suffering from severe MR. Only 2% of the 4.5 million severe MR patients undergo open heart surgery. The remaining 98% are sent home with drug therapy alone, resulting in nearly 50% of them dying within 2 years. The current available treatments for MR patients with heart failure are limited. Surgical repair and replacement are controversial, and new treatments are insufficient. To learn more about VALFIX Medical visit our website at www.valfixmed.com or contact us directly at info@valfixmed.com

To help all parents build a better future for their kids